Markus Muttenthaler

ORCID

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 20

Top Venues

Journal of medicinal chemistry

Biomedicines

Science signaling

Oncogene

University of Vienna

This page only lists publications with an associated author ORCID identifier.

Affiliation History

University of Vienna

Austria

Associate Professor :: Institute of Biological Chemistry

University of Queensland

Australia

Research Group Leader :: Institute for Molecular Bioscience

Publications

Bernhard Jandl, Rebecca Zheng, Markus Muttenthaler, Jonathan B Baell
Novel Diacyl-hydrazide Compounds as Potential Therapeutics for Visceral Leishmaniasis. ACS omega 9 (35) (2024)
Predrag Kalaba, Cristina Sanchez de la Rosa, Andreas Möller, Paul F Alewood, Markus Muttenthaler
Targeting the Oxytocin Receptor for Breast Cancer Management: A Niche for Peptide Tracers. Journal of medicinal chemistry 67 (3) (2024)
Predrag Kalaba, Cristina Sanchez de la Rosa, Andreas Möller, Paul F Alewood, Markus Muttenthaler
Targeting the Oxytocin Receptor for Breast Cancer Management: A Niche for Peptide Tracers. Journal of medicinal chemistry 67 (3) (2024)
Predrag Kalaba, Cristina Sanchez de la Rosa, Andreas Möller, Paul F Alewood, Markus Muttenthaler
Targeting the Oxytocin Receptor for Breast Cancer Management: A Niche for Peptide Tracers. Journal of medicinal chemistry (2024)
Bernhard Jandl, Satish Dighe, Christoph Gasche, Athanasios Makristathis, Markus Muttenthaler
Intestinal biofilms: pathophysiological relevance, host defense, and therapeutic opportunities. Clinical microbiology reviews (2024)
Predrag Kalaba, Cristina Sanchez de la Rosa, Andreas Möller, Paul F Alewood, Markus Muttenthaler
Targeting the Oxytocin Receptor for Breast Cancer Management: A Niche for Peptide Tracers. Journal of medicinal chemistry 67 (3) (2024)
Predrag Kalaba, Cristina Sanchez de la Rosa, Andreas Möller, Paul F Alewood, Markus Muttenthaler
Targeting the Oxytocin Receptor for Breast Cancer Management: A Niche for Peptide Tracers. Journal of medicinal chemistry 67 (3) (2024)
Ulrike Wirth, Konstantin Raabe, Predrag Kalaba, Erik Keimpema, Markus Muttenthaler, Burkhard König
Photoswitchable Probes of Oxytocin and Vasopressin. Journal of medicinal chemistry (2023)
Huiping Liu, Markus Muttenthaler
High Oxytocin Receptor Expression Linked to Increased Cell Migration and Reduced Survival in Patients with Triple-Negative Breast Cancer. Biomedicines 10 (7) (2022)
Thomas Kremsmayr, Aws Aljnabi, Juan B Blanco-Canosa, Hue N T Tran, Nayara Braga Emidio, Markus Muttenthaler
On the Utility of Chemical Strategies to Improve Peptide Gut Stability. Journal of medicinal chemistry 65 (8) (2022)
Anke Hering, Nayara Braga Emidio, Markus Muttenthaler
Expanding the versatility and scope of the oxime ligation: rapid bioconjugation to disulfide-rich peptides. Chemical communications (Cambridge, England) 58 (65) (2022)
Zoltan Dekan, Thomas Kremsmayr, Peter Keov, Mathilde Godin, Ngari Teakle, Leopold Dürrauer, Huang Xiang, Dalia Gharib, Christian Bergmayr, Roland Hellinger, Marina Gay, Marta Vilaseca, Dennis Kurzbach, Fernando Albericio, Paul F Alewood, Christian W Gruber, Markus Muttenthaler
Nature-inspired dimerization as a strategy to modulate neuropeptide pharmacology exemplified with vasopressin and oxytocin. Chemical science 12 (11) (2021)
Nayara Braga Emidio, Rajeshwari Meli, Hue N T Tran, Hayeon Baik, Séverine Morisset-Lopez, Alysha G Elliott, Mark A T Blaskovich, Sabrina Spiller, Annette G Beck-Sickinger, Christina I Schroeder, Markus Muttenthaler
Chemical Synthesis of TFF3 Reveals Novel Mechanistic Insights and a Gut-Stable Metabolite. Journal of medicinal chemistry 64 (13) (2021)
Nayara Braga Emidio, Hue N T Tran, Asa Andersson, Phillip E Dawson, Fernando Albericio, Irina Vetter, Markus Muttenthaler
Improving the Gastrointestinal Stability of Linaclotide. Journal of medicinal chemistry 64 (12) (2021)
Markus Muttenthaler, Glenn F King, David J Adams, Paul F Alewood
Trends in peptide drug discovery. Nature reviews. Drug discovery 20 (4) (2021)
Jörn Heuer, Franziska Heuer, René Stürmer, Sönke Harder, Hartmut Schlüter, Nayara Braga Emidio, Markus Muttenthaler, Dörthe Jechorek, Frank Meyer, Werner Hoffmann
The Tumor Suppressor TFF1 Occurs in Different Forms and Interacts with Multiple Partners in the Human Gastric Mucus Barrier: Indications for Diverse Protective Functions. International journal of molecular sciences 21 (7) (2020)
Alicia Peschel, Fernanda Caldas Cardoso, Andrew A Walker, Thomas Durek, M Rhia L Stone, Nayara Braga Emidio, Phillip E Dawson, Markus Muttenthaler, Glenn F King
Two for the Price of One: Heterobivalent Ligand Design Targeting Two Binding Sites on Voltage-Gated Sodium Channels Slows Ligand Dissociation and Enhances Potency. Journal of medicinal chemistry 63 (21) (2020)
Huiping Liu, Christian W Gruber, Paul F Alewood, Andreas Möller, Markus Muttenthaler
The oxytocin receptor signalling system and breast cancer: a critical review. Oncogene 39 (37) (2020)
Ai-Hua Jin, Markus Muttenthaler, Sebastien Dutertre, S W A Himaya, Quentin Kaas, David J Craik, Richard J Lewis, Paul F Alewood
Conotoxins: Chemistry and Biology. Chemical reviews 119 (21) (2019)
Markus Muttenthaler, Åsa Andersson, Irina Vetter, Rohit Menon, Marta Busnelli, Lotten Ragnarsson, Christian Bergmayr, Sarah Arrowsmith, Jennifer R Deuis, Han Sheng Chiu, Nathan J Palpant, Margaret O'Brien, Terry J Smith, Susan Wray, Inga D Neumann, Christian W Gruber, Richard James Lewis, Paul F Alewood
Subtle modifications to oxytocin produce ligands that retain potency and improved selectivity across species. Science signaling 10 (508) (2017)

Markus Muttenthaler.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Markus Muttenthaler